Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-Pola-ZLP in Previously Untreated DLBCL
NCT06665217Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Jan 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
A Phase 2 trial of glofitamab, polatuzumab vedotin, zanubrutinib, lenalidomide in diffuse large B-cell lymphoma (DLBCL). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
glofitamabpolatuzumab vedotinzanubrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06665217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665217.